Compare RLAY & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLAY | WEN |
|---|---|---|
| Founded | 2015 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2020 | N/A |
| Metric | RLAY | WEN |
|---|---|---|
| Price | $9.15 | $7.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 21 |
| Target Price | ★ $15.75 | $9.76 |
| AVG Volume (30 Days) | 2.5M | ★ 7.2M |
| Earning Date | 02-24-2026 | 02-13-2026 |
| Dividend Yield | N/A | ★ 7.16% |
| EPS Growth | N/A | ★ 0.63 |
| EPS | N/A | ★ 0.95 |
| Revenue | $8,355,000.00 | ★ $2,208,190,000.00 |
| Revenue This Year | $19.96 | N/A |
| Revenue Next Year | N/A | $2.79 |
| P/E Ratio | ★ N/A | $8.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.78 | $7.60 |
| 52 Week High | $9.25 | $16.20 |
| Indicator | RLAY | WEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 46.07 |
| Support Level | $8.08 | $7.60 |
| Resistance Level | $9.25 | $8.24 |
| Average True Range (ATR) | 0.67 | 0.27 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 83.02 | 39.44 |
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.